EMA Authorised: Memantine Mylan (memantine hydrochloride) — Mylan Pharmaceuticals Limited

View source ↗

Summary

EMA authorised Memantine Mylan (memantine hydrochloride) for Alzheimer's disease. The marketing authorization holder is Mylan Pharmaceuticals Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Memantine Mylan (memantine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Alzheimer Disease. MAH: Mylan Pharmaceuticals Limited. Decision date: 27/11/2025